Navigation Links
Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
Date:11/6/2007

LINCOLN, R.I., Nov. 6 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today the completion of enrollment of three on-going clinical studies. Each study is evaluating NT-501, the Company's lead product, for the treatment of visual loss associated with retinitis pigmentosa (RP) and the dry form of age-related macular degeneration (dry AMD). NT-501 is an intraocular, cell containing polymer implant designed to provide the continuous, long-term release of the therapeutic protein, Ciliary Neurotrophic Factor (CNTF), directly into the back of the eye by means of the Company's proprietary Encapsulated Cell Technology (ECT).

"This is a very significant achievement for the Company and a critical milestone in the development of NT-501," said Ted Danse, President and CEO of Neurotech. "We are very pleased with how quickly enrollment was completed for all three clinical studies and we anticipate announcing top line results for these studies by the end of FY 2008."

"The Foundation Fighting Blindness has been a key partner in both the preclinical and clinical studies of the NT-501," said Stephen Rose, Ph.D., Chief Research Officer of the Foundation. "We are particularly excited about Neurotech's treatment, because it holds promise for saving the vision of people affected by a range of retinal degenerative diseases."

RP is an inherited disease that causes the retina's rod and cone photoreceptors to gradually degenerate leading to loss of vision and blindness. The symptoms of RP predominately appear in young adults and affect approximately 100,000 people in the United States and over 1 million people worldwide. At this time there is no known cure or effective treatment for RP.

AMD is a chronic progressive disease of the macula that results in the loss of central vision. It is the leading cause of blindness in elderly people in the d
'/>"/>

SOURCE Neurotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Neurotechnology Industry Organization Unveils Top 10 Neuroscience Trends of 2007
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...athy Tune Promoted to Principal. Christine Siu an... , MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn...artners, a health care venture capital firm that i...anies, today announced the promotion of three memb...romoted to Principal. Christine Siu and Jason Bro...
(Date:1/8/2009)...NDIANAPOLIS, Jan. 8 A p...na Soldiers and Sailors Children,s Home has prompt...f Indiana to revamp its annual Mid-Winter conferen...oordinate its members, nearly unanimous opposition...y provides more than $50,000 in direct and in-kind...
(Date:1/8/2009)... MILWAUKEE, Jan. 8 The physician...ractice with clinics in three northern Illinois,c...ing Aurora Health Care . , (Photo: http:/..., The five internal medicine physicians serv...munities of Gurnee, Lindenhurst and Fox Lake. ,...
(Date:1/8/2009)...RLINGTON, Va., Jan. 8 A...itiative for home medical equipment -- already the...duce homecare costs will only succeed in reducing ...nd will drive up costs elsewhere in Medicare. Wa...olumn on healthcare overlooks the inherent flaws i...
Breaking Medicine News(10 mins):Health News:Thomas, McNerney & Partners Promotes Three Members of Its Investment Team 2Health News:Northern Lake Medical to Join Aurora Health Care 2Health News:Northern Lake Medical to Join Aurora Health Care 3Health News:George Will Column Misguided in Touting 'Competitive Bidding' as a Medicare Solution; Controversial Bidding Program is Actually Anti-Competitive and Lowers Quality of Care and Access to Care for Seniors and Disabled 2Health News:George Will Column Misguided in Touting 'Competitive Bidding' as a Medicare Solution; Controversial Bidding Program is Actually Anti-Competitive and Lowers Quality of Care and Access to Care for Seniors and Disabled 3Health News:George Will Column Misguided in Touting 'Competitive Bidding' as a Medicare Solution; Controversial Bidding Program is Actually Anti-Competitive and Lowers Quality of Care and Access to Care for Seniors and Disabled 4
...s premier school board is set to introduce from th...ge course from Class VI to VIII.// According to th... move will help students in more than one way. "In... foreign languages has become a necessary tool to ...
...use of Commons vote to impose a ban on smoking in ... of researchers measured the air quality, using a ...of England, in areas where smoking was permitted. ... air was very poor, with a very high particles rat...
...ng that the key to good health is the magic word’ ...ad for health//. New England Research Institutes i...rchers, commenting upon Optimum Sleep requirement,...o little can easily become victims of Type 2 diabe...
...e, and do not like it much! According to a new stu.../ may face an increased risk of suffering a heart ...chances of urban middle-aged adults, living on h... din, stood a 46 percent chance of suffering heart...
Other Medicine News:Health News:Schools set to offer Japanese language course 2
(Date:1/6/2009)...an. 6 Pacira Pharmaceuticals, Inc.... announced today that enrollment,has been complet...ate the,safety and efficacy of a single intraoper...ine) for prolonged postoperative analgesia. , ...d in total knee,arthroplasty (TKA) are expected t...
(Date:1/5/2009)... 5 Micromet, Inc.,(Nasd...ng novel, proprietary,antibodies for the treatmen...,provides an outlook on key events anticipated fo...ovide an update on its research and development,p... 12 to 16, 2009: Update on several preclinical BiT...
(Date:12/30/2008)...Newswire-USNewswire/ -- The Coalition for 21st Cen...n filed by Genentech, Inc. on December 5, 2008, se...ffer diagnostic tests to physicians and patients. ...sts, would harm patient care and rests on flawed s...,s mission is to encourage the research, developme...
(Date:12/27/2008)...Dec. 27 According to the latest,s... consume modest doses of,resveratrol plus an arra...n 3,to 5 glasses of aged, red wine, rather than r...wscom.com/cgi-bin/prnh/20080603/LATU039 ) , ...l alone fails to prolong,the life of laboratory m...
Breaking Medicine Technology:Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3Nurse Practitioner Fights Back as 113 Million U S Households Face Risk of Contamination 32287 1Nurse Practitioner Fights Back as 113 Million U S Households Face Risk of Contamination 32287 2City of Newark Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 32285 1City of Newark Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 32285 2City of Newark Ohio Increases Safety Services with EMS Revenue Recovered by MED3OOO EMS Billing 32285 3Quitting Smoking Can Be a Parents Best New Years Resolution 32284 1Quitting Smoking Can Be a Parents Best New Years Resolution 32284 2Quitting Smoking Can Be a Parents Best New Years Resolution 32284 3Quitting Smoking Can Be a Parents Best New Years Resolution 32284 4CeloNova BioSciences Receives FDA Market Approval for Embozene 28TM 29 Color Advanced Microspheres Embolization Platform 32282 1CeloNova BioSciences Receives FDA Market Approval for Embozene 28TM 29 Color Advanced Microspheres Embolization Platform 32282 2CeloNova BioSciences Receives FDA Market Approval for Embozene 28TM 29 Color Advanced Microspheres Embolization Platform 32282 3CeloNova BioSciences Receives FDA Market Approval for Embozene 28TM 29 Color Advanced Microspheres Embolization Platform 32282 4
...ms and Urine Flow, With,Long Lasting Effect in Pha...re-FirstCall/ -- Spectrum,Pharmaceuticals, Inc., t...r ozarelix, the Company,s drug candidate for the t... the American Urology,Association Annual Meeting h...alifornia on Tuesday, May 22, 2007. , "The results...
...ncer Studies; 9 Targeted,Agent Studies, INDIANAPOL...ncology will unveil 76 studies at the 43rd Annual ...gy (ASCO) in Chicago, Ill. from,June 1-5, 2007. Th... (gemcitabine HCl for injection), ALIMTA(R) (pemet...ational, oral, targeted,therapy. There will also b...
Other Medicine Technology:Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007 2
...r N395 Pulse Oximeter with Oxismart XL Advanced Si...onditions, cutting through nonspecific noise to fi...values. , ,The N395 monitor is also equipped ...n clinician-programmable alarm sensitivity for pul...
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery.
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery.
After inserting a finger into comfortable holder, measuring switch is automatically turned on, and continuous measurement is performed., ,Large display of approx. 11mm character height. In darke
Medicine Products: